Recent News
On May 19, 2026 Lantheus announced data to be presented at the 2026 American Society of Clinical Oncology Annual Meeting. On May 21, 2026 the company highlighted new radiodiagnostic data to be presented at the 2026 Society of Nuclear Medicine and Medical Imaging Annual Meeting. On June 26, 2026 Lantheus disclosed receipt of a Complete Response Letter from the FDA for LNTH-2501, citing unresolved third‑party facility manufacturing conditions that prevent approval at the current PDUFA date.
Technical Analysis
ADX at 14.39 indicates no established market trend; momentum lacks directional strength, leaving price action susceptible to news-driven moves rather than sustained technical thrusts.
DI+ at 20.20 shows increasing directional interest, while DI– at 24.62 has completed a peak-and-reversal; the combination reads as a recovering directional bias that supports a bullish tilt if trend strength rises from current low levels.
MACD at –0.70 with a decreasing trajectory and a signal line at –0.22 indicates prevailing bearish momentum; the MACD sits below its signal line, signaling that short-term momentum remains negative despite directional indicator signals.
MRO at –13.82 (dip-and-reversal) signals the stock trades below a regression-based target and therefore carries upward potential toward that target, creating a technical divergence versus the declining MACD.
RSI at 50.64 and falling denotes waning upside pressure; the reading sits near neutral, implying limited immediate momentum and the potential for range-bound action until momentum reasserts.
Price rests below the 12‑day EMA (12‑day EMA = $101.89, price close = $100.98) with the 20‑day and 50‑day averages near $102–$104; price above the 200‑day average ($79.89) preserves longer-term strength while short-term moving averages show mild downward pressure.
Bollinger bands place the close roughly mid‑band (upper ~ $104.81, lower ~ $99.65), consistent with consolidation inside a moderate volatility envelope; volume at ~1.40M sits below the 10‑day average, signaling muted conviction on the intraday move.
Fundamental Analysis
Profitability shows core strength: operating margin at 25.82% and EBIT margin at 25.44% both exceed the industry peer mean and sit above the industry peer median, indicating above‑peer operating profitability. QoQ, EBIT margin contracted by 40.48% and YoY declined by 12.13%, reflecting recent margin compression versus prior periods.
Revenue totaled $388.18M with year‑over‑year revenue growth of 102.89% and sequential revenue change of 2.88%; the YoY figure implies a large comparability effect year over year while the QoQ measure shows modest sequential expansion.
EPS actual of $1.55 beat the estimate of $1.30 by $0.25, a 19.23% surprise, supporting near‑term fundamental resilience in reported profitability and cash generation.
Liquidity and leverage present a constructive mix: cash and short‑term investments $593.30M, current ratio 3.06 and quick ratio 2.89 indicate ample near‑term liquidity; total debt $624.96M yields debt‑to‑EBITDA of 5.15 and debt‑to‑equity of 0.48, which sits slightly above the industry peer mean for debt‑to‑equity but within the industry peer range for debt metrics.
Cash flow metrics show operating cash flow $92.20M and free cash flow $89.87M with free cash flow yield 1.38%, above the industry peer mean free cash flow yield of 1.01%, supporting the balance sheet despite a QoQ decline in free cash flow yield.
Returns remain modest: return on equity 5.72% sits below the industry peer mean of 6.67%, while return on assets 3.15% exceeds the industry peer mean of 1.91%, suggesting capital efficiency in asset use but room to improve shareholder returns.
Valuation context: enterprise value to revenue and PE multiples run rich relative to typical health‑care equipment norms (PE ~64.35, EV/Revenue ~16.85); the current valuation as determined by WMDST registers as over‑valued, while the analyst price target mean in the data sits at $115.93, leaving a measurable gap between market price and consensus targets.
MOST-RECENT QUARTERLY REPORT
| REPORT PERIOD ENDING: | 2026-06-30 |
| REPORT DATE: | 2026-08-06 |
| NEXT REPORT DATE: | 2026-11-05 |
| CASH FLOW | Begin Period Cash Flow | $ 500.3 M |
| Operating Cash Flow | $ 92.2 M | |
| Capital Expenditures | $ -2.33 M | |
| Change In Working Capital | $ 11.1 M | |
| Dividends Paid | — | |
| Cash Flow Delta | $ 94.7 M | |
| End Period Cash Flow | $ 595.0 M | |
| INCOME STATEMENT | REVENUE | |
| Total Revenue | $ 388.2 M | |
| Forward Revenue | $ 133.2 M | |
| COSTS | ||
| Cost Of Revenue | $ 146.3 M | |
| Depreciation | $ 22.6 M | |
| Depreciation and Amortization | $ 22.6 M | |
| Research and Development | $ 38.2 M | |
| Total Operating Expenses | $ 288.0 M | |
| PROFITABILITY | ||
| Gross Profit | $ 241.9 M | |
| EBITDA | $ 121.3 M | |
| EBIT | $ 98.7 M | |
| Operating Income | $ 100.2 M | |
| Interest Income | $ 6.3 M | |
| Interest Expense | $ 4.9 M | |
| Net Interest Income | $ 1.3 M | |
| Income Before Tax | $ 93.8 M | |
| Tax Provision | $ 18.8 M | |
| Tax Rate | 20.033 % | |
| Net Income | $ 75.0 M | |
| Net Income From Continuing Operations | $ 75.0 M | |
| EARNINGS | ||
| EPS Estimate | $ 1.30 | |
| EPS Actual | $ 1.55 | |
| EPS Difference | $ 0.25 | |
| EPS Surprise | 19.231 % | |
| Forward EPS | $ 1.58 | |
| BALANCE SHEET | ASSETS | |
| Total Assets | $ 2.4 B | |
| Intangible Assets | $ 928.4 M | |
| Net Tangible Assets | $ 383.4 M | |
| Total Current Assets | $ 1.0 B | |
| Cash and Short-Term Investments | $ 593.3 M | |
| Cash | $ 593.3 M | |
| Net Receivables | $ 352.9 M | |
| Inventory | $ 57.6 M | |
| Long-Term Investments | $ 59.7 M | |
| LIABILITIES | ||
| Accounts Payable | $ 48.1 M | |
| Short-Term Debt | $ 697.0 K | |
| Total Current Liabilities | $ 335.7 M | |
| Net Debt | — | |
| Total Debt | $ 625.0 M | |
| Total Liabilities | $ 1.1 B | |
| EQUITY | ||
| Total Equity | $ 1.3 B | |
| Retained Earnings | $ 873.0 M | |
| VALUATION & PER-SHARE METRICS | EQUITY & PER-SHARE METRICS | |
| Book Value Per-Share | $ 20.10 | |
| Shares Outstanding | 65.265 M | |
| Revenue Per-Share | $ 5.95 | |
| VALUATION | Market Capitalization | $ 6.5 B |
| Enterprise Value | $ 6.5 B | |
| Enterprise Multiple | 53.921 | |
| Enterprise Multiple QoQ | 90.575 % | |
| Enterprise Multiple YoY | 43.947 % | |
| Enterprise Multiple IPRWA | high: 510.258 mean: 67.679 median: 55.135 LNTH: 53.921 low: -170.556 |
|
| EV/R | 16.852 | |
| CAPITAL STRUCTURE | ||
| Asset To Equity | 1.841 | |
| Asset To Liability | 2.189 | |
| Debt To Capital | 0.323 | |
| Debt To Assets | 0.259 | |
| Debt To Assets QoQ | -2.94 % | |
| Debt To Assets YoY | -11.019 % | |
| Debt To Assets IPRWA | high: 1.015 median: 0.301 mean: 0.284 LNTH: 0.259 low: 0.018 |
|
| Debt To Equity | 0.476 | |
| Debt To Equity QoQ | -7.701 % | |
| Debt To Equity YoY | -9.685 % | |
| Debt To Equity IPRWA | high: 1.558 median: 0.565 LNTH: 0.476 mean: 0.452 low: -0.505 |
|
| PRICE-BASED VALUATION | ||
| Price To Book (P/B) | 4.963 | |
| Price To Book QoQ | 18.49 % | |
| Price To Book YoY | 23.863 % | |
| Price To Book IPRWA | high: 21.577 mean: 5.48 LNTH: 4.963 median: 2.286 low: -4.924 |
|
| Price To Earnings (P/E) | 64.354 | |
| Price To Earnings QoQ | 48.458 % | |
| Price To Earnings YoY | -9.458 % | |
| Price To Earnings IPRWA | high: 344.308 mean: 70.955 LNTH: 64.354 median: 49.315 low: -330.559 |
|
| PE/G Ratio | 10.44 | |
| Price To Sales (P/S) | 16.771 | |
| Price To Sales QoQ | 24.632 % | |
| Price To Sales YoY | 35.62 % | |
| Price To Sales IPRWA | high: 66.384 mean: 22.563 LNTH: 16.771 median: 14.212 low: 2.063 |
|
| FORWARD MULTIPLES | ||
| Forward P/E | 59.703 | |
| Forward PE/G | 9.686 | |
| Forward P/S | 48.892 | |
| EFFICIENCY | OPERATIONAL | |
| Operating Leverage | -13.488 | |
| ASSET & SALES | ||
| Asset Turnover Ratio | 0.163 | |
| Asset Turnover Ratio QoQ | -1.17 % | |
| Asset Turnover Ratio YoY | -10.041 % | |
| Asset Turnover Ratio IPRWA | high: 0.581 mean: 0.196 LNTH: 0.163 median: 0.162 low: 0.001 |
|
| Receivables Turnover | 1.096 | |
| Receivables Turnover Ratio QoQ | 3.71 % | |
| Receivables Turnover Ratio YoY | -0.684 % | |
| Receivables Turnover Ratio IPRWA | high: 3.342 mean: 1.629 median: 1.509 LNTH: 1.096 low: 0.261 |
|
| Inventory Turnover | 2.462 | |
| Inventory Turnover Ratio QoQ | 5.929 % | |
| Inventory Turnover Ratio YoY | 17.911 % | |
| Inventory Turnover Ratio IPRWA | high: 2.735 LNTH: 2.462 mean: 0.812 median: 0.699 low: 0.055 |
|
| Days Sales Outstanding (DSO) | 83.28 | |
| CASH CYCLE | ||
| Cash Conversion Cycle Days (CCC) | 91.042 | |
| Cash Conversion Cycle Days QoQ | -5.762 % | |
| Cash Conversion Cycle Days YoY | -7.182 % | |
| Cash Conversion Cycle Days IPRWA | high: 341.798 mean: 131.587 median: 119.382 LNTH: 91.042 low: -70.443 |
|
| CAPITAL DEPLOYMENT | ||
| Cash Conversion Ratio | 0.561 | |
| CapEx To Revenue | -0.006 | |
| CapEx To Depreciation | -0.103 | |
| CAPITAL, LIQUIDITY & COVERAGE | CAPITAL STRUCTURE | |
| Total Capital | $ 1.9 B | |
| Net Invested Capital | $ 1.9 B | |
| Invested Capital | $ 1.9 B | |
| Net Tangible Assets | $ 383.4 M | |
| Net Working Capital | $ 691.4 M | |
| LIQUIDITY | ||
| Cash Ratio | 1.767 | |
| Current Ratio | 3.06 | |
| Current Ratio QoQ | 8.181 % | |
| Current Ratio YoY | -28.682 % | |
| Current Ratio IPRWA | high: 11.702 LNTH: 3.06 mean: 2.503 median: 2.126 low: 0.413 |
|
| Quick Ratio | 2.888 | |
| Quick Ratio QoQ | 9.23 % | |
| Quick Ratio YoY | -29.007 % | |
| Quick Ratio IPRWA | high: 11.177 LNTH: 2.888 mean: 1.981 median: 1.616 low: 0.336 |
|
| COVERAGE & LEVERAGE | ||
| Debt To EBITDA | 5.151 | |
| Cost Of Debt | 0.629 % | |
| Interest Coverage Ratio | 20.09 | |
| Interest Coverage Ratio QoQ | -39.408 % | |
| Interest Coverage Ratio YoY | -9.735 % | |
| Interest Coverage Ratio IPRWA | high: 70.269 LNTH: 20.09 median: 11.42 mean: 4.952 low: -88.121 |
|
| Operating Cash Flow Ratio | 0.317 | |
| TIMING / LIQUIDITY | ||
| Days Payables Outstanding (DPO) | 29.288 | |
| DIVIDENDS | ||
| Dividend Coverage Ratio | — | |
| Dividend Payout Ratio | — | |
| Dividend Rate | — | |
| Dividend Yield | — | |
| PERFORMANCE | GROWTH | |
| Asset Growth Rate | 2.901 % | |
| Revenue Growth | 2.875 % | |
| Revenue Growth QoQ | -139.71 % | |
| Revenue Growth YoY | 102.893 % | |
| Revenue Growth IPRWA | high: 28.183 % median: 8.761 % mean: 8.497 % LNTH: 2.875 % low: -6.025 % |
|
| Earnings Growth | 6.164 % | |
| Earnings Growth QoQ | -20.812 % | |
| Earnings Growth YoY | -37.128 % | |
| Earnings Growth IPRWA | high: 200.0 % mean: 21.881 % median: 8.108 % LNTH: 6.164 % low: -81.25 % |
|
| MARGINS | ||
| Gross Margin | 62.305 % | |
| Gross Margin QoQ | 1.809 % | |
| Gross Margin YoY | -2.27 % | |
| Gross Margin IPRWA | high: 89.754 % median: 64.456 % LNTH: 62.305 % mean: 59.847 % low: 31.392 % |
|
| EBIT Margin | 25.437 % | |
| EBIT Margin QoQ | -40.483 % | |
| EBIT Margin YoY | -12.126 % | |
| EBIT Margin IPRWA | high: 35.132 % LNTH: 25.437 % median: 20.496 % mean: 13.362 % low: -67.441 % |
|
| Return On Sales (ROS) | 25.817 % | |
| Return On Sales QoQ | 19.784 % | |
| Return On Sales YoY | 10.95 % | |
| Return On Sales IPRWA | high: 34.98 % LNTH: 25.817 % median: 20.526 % mean: 13.052 % low: -86.026 % |
|
| CASH FLOW | ||
| Free Cash Flow (FCF) | $ 89.9 M | |
| Free Cash Flow Yield | 1.38 % | |
| Free Cash Flow Yield QoQ | -42.524 % | |
| Free Cash Flow Yield YoY | -12.492 % | |
| Free Cash Flow Yield IPRWA | high: 7.0 % LNTH: 1.38 % median: 1.089 % mean: 1.01 % low: -8.727 % |
|
| Free Cash Growth | -26.278 % | |
| Free Cash Growth QoQ | -152.795 % | |
| Free Cash Growth YoY | 3.432 % | |
| Free Cash Growth IPRWA | high: 776.0 % mean: 32.98 % median: -9.348 % LNTH: -26.278 % low: -919.099 % |
|
| Free Cash To Net Income | 1.198 | |
| Cash Flow Margin | 27.413 % | |
| Cash Flow To Earnings | 1.418 | |
| VALUE & RETURNS | ||
| Economic Value Added | $ 0.04 | |
| Return On Assets (ROA) | 3.152 % | |
| Return On Assets QoQ | -39.127 % | |
| Return On Assets YoY | -16.525 % | |
| Return On Assets IPRWA | high: 10.633 % LNTH: 3.152 % mean: 1.913 % median: 1.348 % low: -18.798 % |
|
| Return On Capital Employed (ROCE) | 4.749 % | |
| Return On Equity (ROE) | 0.057 | |
| Return On Equity QoQ | -41.441 % | |
| Return On Equity YoY | -15.259 % | |
| Return On Equity IPRWA | high: 0.539 mean: 0.067 LNTH: 0.057 median: 0.025 low: -0.257 |
|
| DuPont ROE | 5.945 % | |
| Return On Invested Capital (ROIC) | 4.194 % | |
| Return On Invested Capital QoQ | -38.765 % | |
| Return On Invested Capital YoY | -11.78 % | |
| Return On Invested Capital IPRWA | high: 13.429 % LNTH: 4.194 % mean: 3.004 % median: 1.784 % low: -12.224 % |
|